Magnitude and Breadth of a Nonprotective Neutralizing Antibody Response in an Efficacy Trial of a Candidate HIV‐1 gp120 Vaccine
Open Access
- 15 August 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 202 (4) , 595-605
- https://doi.org/10.1086/654816
Abstract
Background. A candidate vaccine consisting of human immunodeficiency virus type 1 (HIV-1) subunit gp120 protein was found previously to be nonprotectiKeywords
This publication has 47 references indexed in Scilit:
- The Role of Antibodies in HIV VaccinesAnnual Review of Immunology, 2010
- Development of an HIV-1 Reference Panel of Subtype B Envelope Clones Isolated From the Plasma of Recently Infected IndividualsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2007
- Randomized, Double‐Blind, Placebo‐Controlled Efficacy Trial of a Bivalent Recombinant Glycoprotein 120 HIV‐1 Vaccine among Injection Drug Users in Bangkok, ThailandThe Journal of Infectious Diseases, 2006
- Antibody Binding Is a Dominant Determinant of the Efficiency of Human Immunodeficiency Virus Type 1 NeutralizationJournal of Virology, 2006
- HIV VACCINESAnnual Review of Immunology, 2006
- Urgently needed: a filter for the HIV-1 vaccine pipelineNature Medicine, 2004
- Antibody neutralization and escape by HIV-1Nature, 2003
- Development of bivalent rgp120 vaccines to prevent HIV type 1 infection.1998
- Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3.1998
- Two Antigenically Distinct Subtypes of Human Immunodeficiency Virus Type 1: Viral Genotype Predicts Neutralization SerotypeThe Journal of Infectious Diseases, 1994